This article reports the results of second stage clinical trial on the treatment of peptic ulcer with jian-wei yu-yang (JWYY) tablets in comparison with a control group treated with ranitidine. The results showed that the cure rate for JWYY tablet group was 62.4% and its effective rate was 93. 8% in 354 cases, whereas the cure rate of the control group was 50.7% and its effective rate was 86. 4% in 140 cases. The differences between these two groups were highly significant (P less than 0.01). Based on syndrome differentiation, optimal effect was reached in treating liver stagnation and spleen deficiency syndrome and disharmony of liver and stomach syndrome. After one year follow up studies of the therapeutic effect, the recurrence rate of the JWYY tablet group was 17.7%, while that of the ranitidine group was 54.1%. In addition, JWYY tablet had no side-effects. These data indicated that JWYY tablets were a more effective therapeutic remedy for peptic ulcer.